ImmunoCellular to add EphA2 antigen from Pitt to cancer vaccine cocktail
This article was originally published in Scrip
Executive Summary
With a license from the University of Pittsburgh for the tyrosine kinase receptor, ImmunoCellular Therapeutics picked up one more antigen to mix in the cocktail it's formulating for a cancer vaccine.